Comment on “Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis” J.M.P.A. van den Reek, W. Kievit, E.M.G.J. de Jong

Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis P. Garbayo Salmons, V. Expósito Serrano, J. Romaní de Gabriel, M. Ribera Pibernat

AEDV BIOBADADERM Registry: 15 Year-Contribution to Psoriasis Therapy Safety D.P. Ruiz-Genao, A. González-Quesada, A. Sahuquillo-Torralba, R. Rivera-Díaz, M.A. Descalzo, I. García-Doval